Green Cross LabCell Applies for Phase 1 Clinical Trial of Stem Cell Therapy for Acute Respiratory Distress Syndrome
[Asia Economy Reporter Minwoo Lee] Green Cross LabCell announced on the 23rd that it has applied to the Ministry of Food and Drug Safety for a Phase 1 clinical trial plan to evaluate the safety, tolerability, and efficacy of a single dose of allogeneic tonsil-derived mesenchymal stem cells (CT303) in patients with acute respiratory distress syndrome. The trial will be multicenter, open-label, dose-escalation, and dose-finding.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "I Will Give Them a Chance for Self-Examination": Chinese Scientific Community Shaken by Influencer's Preemptive Whistleblowing
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The clinical trial institutions include three hospitals: Bundang Seoul National University Hospital, Seoul National University Hospital, and Seoul Metropolitan Boramae Hospital. The company explained, "CT303, the investigational drug manufactured using tonsil tissue collected from healthy donors under 10 years old, is expected to have a therapeutic effect on patients with acute respiratory distress syndrome who exhibit excessive inflammatory responses and cell death, by modulating excessive immune reactions."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
